GE Healthcare grants license for biomagnetic isolation of nucleic acids to NorDiag ASA
According to the company, GE Healthcare's patented methods for magnetic separation offer significant advantages over conventional techniques for the isolation and purification of biomolecules such as DNA and RNA from laboratory and clinical samples. In particular, the proprietary protocols will allow diagnosis from smaller-volume patient samples because they increase the yield of nucleic acid from disease-causing pathogens isolated from patient samples.
"This license recognizes the considerable value that our biomagnetic isolation technology can bring to the diagnosis of infectious diseases," said Eric Roman, General Manager, Genomic Sciences, GE Healthcare. "We are pleased to grant NorDiag ASA access to our patents in this area, which will allow them to commercialise products that can isolate nucleic acids from difficult clinical samples."
Financial terms were not disclosed.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.